COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

Mostrar otras versiones (1)

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both m...

Descripción completa

Detalles Bibliográficos
Autores principales: Malone, Robert W., Tisdall, Philip, Fremont-Smith, Philip, Liu, Yongfeng, Huang, Xi-Ping, White, Kris M., Miorin, Lisa, Del Olmo, Elena Moreno, Alon, Assaf, Delaforge, Elise, Hennecker, Christopher D., Wang, Guanyu, Pottel, Joshua, Smith, Nora, Hall, Julie M., Shapiro, Gideon, Mittermaier, Anthony, Kruse, Andrew C., García-Sastre, Adolfo, Roth, Bryan L., Glasspool-Malone, Jill, Ricke, Darrell O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336703/
https://www.ncbi.nlm.nih.gov/pubmed/32702719
http://dx.doi.org/10.21203/rs.3.rs-30934/v3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336703/
https://www.ncbi.nlm.nih.gov/pubmed/32702719
http://dx.doi.org/10.21203/rs.3.rs-30934/v3

Ejemplares similares